Strategy Documents

Annex to the GLG report: Estimating the return on investment from tackling antimicrobial resistance using a package of One Health interventions

4 April 2024

| Position paper

Annex to the GLG report: Estimating the return on investment from tackling antimicrobial resistance using a package of One Health interventions

Overview

With the current level of action, it is projected that antimicrobial resistance (AMR) will lead to a reduction in life expectancy of 1.8 years globally by 2035.

It will be met with significantly higher healthcare costs, with annual expenses for treating resistant bacterial infections estimated to reach US$ 412 billion worldwide.
The increase in morbidity and mortality resulting from these bacterial infections will impose economic losses of US$ 443 billion from reduced workforce productivity alone.
Evaluation of a mixed policy of One Health interventions – including awareness raising, surveillance, optimizing antimicrobial use in human and animal health, infection prevention, and new treatments – suggests a potential to avert nearly US$ 7.7 trillion in losses deriving from healthcare expenditure and workforce productivity by 2035. Implemented for longer, these interventions would offset another US$ 615.5 billion in losses per year, resulting in cumulative gains of US$ 19.1 trillion by 2050.
The One Health intervention package considered in this study is estimated to cost US$ 1,248.1 billion worldwide by 2050, or US$ 40.3 billion per year.
From this perspective in which the economic impact from AMR is measured through changes in healthcare expenditure and general workforce productivity, for every US$ 1 invested in a mixed policy intervention package, a global net return of between US$ 10.9 and US$ 14.2 is expected (2035 and 2050 scenarios respectively).

WHO Team

One Health Global Leaders Group on Antimicrobial Resistance

Information notes

Annex to the GLG report: Estimating the return on investment from tackling antimicrobial resistance using a package of One Health interventions

4 April 2024

| Position paper

Overview

With the current level of action, it is projected that antimicrobial resistance (AMR) will lead to a reduction in life expectancy of 1.8 years globally by 2035.

It will be met with significantly higher healthcare costs, with annual expenses for treating resistant bacterial infections estimated to reach US$ 412 billion worldwide.
The increase in morbidity and mortality resulting from these bacterial infections will impose economic losses of US$ 443 billion from reduced workforce productivity alone.
Evaluation of a mixed policy of One Health interventions – including awareness raising, surveillance, optimizing antimicrobial use in human and animal health, infection prevention, and new treatments – suggests a potential to avert nearly US$ 7.7 trillion in losses deriving from healthcare expenditure and workforce productivity by 2035. Implemented for longer, these interventions would offset another US$ 615.5 billion in losses per year, resulting in cumulative gains of US$ 19.1 trillion by 2050.
The One Health intervention package considered in this study is estimated to cost US$ 1,248.1 billion worldwide by 2050, or US$ 40.3 billion per year.
From this perspective in which the economic impact from AMR is measured through changes in healthcare expenditure and general workforce productivity, for every US$ 1 invested in a mixed policy intervention package, a global net return of between US$ 10.9 and US$ 14.2 is expected (2035 and 2050 scenarios respectively).

WHO Team

One Health Global Leaders Group on Antimicrobial Resistance

Statements and calls to action

Annex to the GLG report: Estimating the return on investment from tackling antimicrobial resistance using a package of One Health interventions

4 April 2024

| Position paper

Overview

With the current level of action, it is projected that antimicrobial resistance (AMR) will lead to a reduction in life expectancy of 1.8 years globally by 2035.

It will be met with significantly higher healthcare costs, with annual expenses for treating resistant bacterial infections estimated to reach US$ 412 billion worldwide.
The increase in morbidity and mortality resulting from these bacterial infections will impose economic losses of US$ 443 billion from reduced workforce productivity alone.
Evaluation of a mixed policy of One Health interventions – including awareness raising, surveillance, optimizing antimicrobial use in human and animal health, infection prevention, and new treatments – suggests a potential to avert nearly US$ 7.7 trillion in losses deriving from healthcare expenditure and workforce productivity by 2035. Implemented for longer, these interventions would offset another US$ 615.5 billion in losses per year, resulting in cumulative gains of US$ 19.1 trillion by 2050.
The One Health intervention package considered in this study is estimated to cost US$ 1,248.1 billion worldwide by 2050, or US$ 40.3 billion per year.
From this perspective in which the economic impact from AMR is measured through changes in healthcare expenditure and general workforce productivity, for every US$ 1 invested in a mixed policy intervention package, a global net return of between US$ 10.9 and US$ 14.2 is expected (2035 and 2050 scenarios respectively).

WHO Team

One Health Global Leaders Group on Antimicrobial Resistance

Meeting reports

Annex to the GLG report: Estimating the return on investment from tackling antimicrobial resistance using a package of One Health interventions

4 April 2024

| Position paper

Overview

With the current level of action, it is projected that antimicrobial resistance (AMR) will lead to a reduction in life expectancy of 1.8 years globally by 2035.

It will be met with significantly higher healthcare costs, with annual expenses for treating resistant bacterial infections estimated to reach US$ 412 billion worldwide.
The increase in morbidity and mortality resulting from these bacterial infections will impose economic losses of US$ 443 billion from reduced workforce productivity alone.
Evaluation of a mixed policy of One Health interventions – including awareness raising, surveillance, optimizing antimicrobial use in human and animal health, infection prevention, and new treatments – suggests a potential to avert nearly US$ 7.7 trillion in losses deriving from healthcare expenditure and workforce productivity by 2035. Implemented for longer, these interventions would offset another US$ 615.5 billion in losses per year, resulting in cumulative gains of US$ 19.1 trillion by 2050.
The One Health intervention package considered in this study is estimated to cost US$ 1,248.1 billion worldwide by 2050, or US$ 40.3 billion per year.
From this perspective in which the economic impact from AMR is measured through changes in healthcare expenditure and general workforce productivity, for every US$ 1 invested in a mixed policy intervention package, a global net return of between US$ 10.9 and US$ 14.2 is expected (2035 and 2050 scenarios respectively).

WHO Team

One Health Global Leaders Group on Antimicrobial Resistance

Presentations and Photos

Presentation from the GLG information Session on the establishment of The Independent Panel on Evidence for Action against Antimicrobial Resistance (IPEA)

Thumbnail for Presentation on the update on the establishment of the IPEA

Representing the Quadripartite Joint Secretariat (QJS), Dr. Sheila Aggarwal-Khan, provided a detailed briefing on the key elements of institutional design...

Download